Trending: Wuxi Biologics Licenses Tumor Antibodies to GSK
05 January 2023 - 04:28PM
Dow Jones News
0458 GMT - Wuxi Biologics (Cayman) Inc. is one of the most
mentioned companies in the news over the past six hours, according
to Factiva data, after it agreed to license T-cell-engaging
antibodies to GSK PLC. Wuxi Biologics said Thursday that the deal
was for exclusive licenses for up to four TCE antibodies. GSK will
make a $40 million up-front payment to Wuxi and up to $1.46 billion
in additional payments for R&D and other milestones along with
tiered royalties on net sales, Wuxi Biologics said. The Chinese
company's Hong Kong shares rose by as much as 7.7% in early trade
before the gains eased to 2.5% ahead of the midday trading break.
Dow Jones & Co. owns Factiva.
(jacques.vanwersch@dowjones.com)
(END) Dow Jones Newswires
January 05, 2023 00:13 ET (05:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024